Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
63 hedge funds and large institutions have $99.7M invested in Unity Biotechnology in 2019 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 18 increasing their positions, 18 reducing their positions, and 6 closing their positions.
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
9% more funds holding
Funds holding: 58 → 63 (+5)
0% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 18
0.08% less ownership
Funds ownership: 3.86% → 3.78% (-0.08%)
37% less capital invested
Capital invested by funds: $157M → $99.7M (-$57.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.46M |
| 2 |
Millennium Management
New York
|
+$1.31M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$944K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$902K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$746K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$7.03M |
| 2 |
Goldman Sachs
New York
|
-$1.77M |
| 3 |
SCM
Sio Capital Management
New York
|
-$956K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$455K |
| 5 |
Morgan Stanley
New York
|
-$268K |
UBX Hedge Fund Activity: Q3 2019 in Review
63 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q3 2019, worth a combined $99.7M — down 37% from $157M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new UBX positions and 6 closed out — a net gain of 6 holders — while 18 added to existing stakes and 18 trimmed.
The largest buyer was Vanguard Group, adding an estimated $2.46M. The largest seller was EcoR1 Capital, cutting an estimated $7.03M.
- 63 institutional investors held Unity Biotechnology (UBX) as of Q3 2019, up from 58 in Q2 2019.
- Funds reported $99.7M of Unity Biotechnology stock for Q3 2019, down 37% quarter-over-quarter.
- 12 funds opened new Unity Biotechnology positions in Q3 2019 and 6 closed out, a net change of +6 holders.
- The largest Unity Biotechnology buyer in Q3 2019 was Vanguard Group, an estimated $2.46M added.
- The largest Unity Biotechnology seller in Q3 2019 was EcoR1 Capital, an estimated $7.03M sold.
Based on aggregated 13F filings for Q3 2019.